How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
65
CRVS Quote, Financials, Valuation and Earnings
Last price:
$20.67
Seasonality move
:
-15.85%
Day range:
$20.20 - $21.71
52-week range:
$2.54 - $26.95
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
21.54x
Volume:
2.4M
Avg. volume:
5.7M
1-year change:
291.3%
Market cap:
$1.5B
Revenue:
--
EPS (TTM):
-$0.53
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CRVS
Corvus Pharmaceuticals, Inc.
|
-- | -$0.13 | -- | -23.82% | $33.33 |
|
GERN
Geron Corp.
|
$50.9M | -$0.05 | 32.79% | -16.11% | $3.60 |
|
JAGX
Jaguar Health, Inc.
|
$4.2M | -$4.26 | 20.18% | -92.94% | $25.50 |
|
KRYS
Krystal Biotech, Inc.
|
$105.5M | $1.61 | 35.17% | 42.95% | $288.70 |
|
PSTV
Plus Therapeutics, Inc.
|
$1.2M | -$0.04 | -1.06% | -93.96% | $6.38 |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.8B | $10.75 | 19.66% | 41.09% | $842.42 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CRVS
Corvus Pharmaceuticals, Inc.
|
$20.70 | $33.33 | $1.5B | -- | $0.00 | 0% | -- |
|
GERN
Geron Corp.
|
$1.37 | $3.60 | $874.5M | -- | $0.00 | 0% | 4.97x |
|
JAGX
Jaguar Health, Inc.
|
$0.67 | $25.50 | $853.2K | -- | $0.00 | 0% | 0.23x |
|
KRYS
Krystal Biotech, Inc.
|
$279.24 | $288.70 | $8.1B | 41.88x | $0.00 | 0% | 22.32x |
|
PSTV
Plus Therapeutics, Inc.
|
$0.23 | $6.38 | $31.3M | -- | $0.00 | 0% | 3.66x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$741.45 | $842.42 | $77.9B | 17.84x | $0.88 | 0.48% | 5.62x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CRVS
Corvus Pharmaceuticals, Inc.
|
1.39% | 3.075 | 0.18% | 8.14x |
|
GERN
Geron Corp.
|
50.25% | 1.450 | 28.73% | 4.76x |
|
JAGX
Jaguar Health, Inc.
|
85.01% | -1.031 | 766.14% | 0.14x |
|
KRYS
Krystal Biotech, Inc.
|
0.83% | -0.755 | 0.19% | 9.43x |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -1.184 | 0.02% | 1.22x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
7.97% | -0.094 | 3.34% | 4.22x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CRVS
Corvus Pharmaceuticals, Inc.
|
-$28K | -$10.6M | -30.03% | -30.6% | -- | -$9.6M |
|
GERN
Geron Corp.
|
$45.9M | -$13.9M | -16.45% | -29.65% | -29.41% | -$13.5M |
|
JAGX
Jaguar Health, Inc.
|
$2M | -$7.2M | -97.4% | -524.57% | -234.77% | -$4.7M |
|
KRYS
Krystal Biotech, Inc.
|
$92.1M | $41.4M | 19.74% | 19.91% | 42.31% | $38M |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.3B | $898.6M | 13.68% | 14.93% | 23.13% | $1.4B |
Corvus Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns CRVS or GERN?
Geron Corp. has a net margin of -- compared to Corvus Pharmaceuticals, Inc.'s net margin of -39.02%. Corvus Pharmaceuticals, Inc.'s return on equity of -30.6% beat Geron Corp.'s return on equity of -29.65%.
Company Gross Margin Earnings Per Share Invested Capital CRVSCorvus Pharmaceuticals, Inc.-- -$0.12 $72.8M GERNGeron Corp.97.13% -$0.03 $500M -
What do Analysts Say About CRVS or GERN?
Corvus Pharmaceuticals, Inc. has a consensus price target of $33.33, signalling upside risk potential of 61.03%. On the other hand Geron Corp. has an analysts' consensus of $3.60 which suggests that it could grow by 162.77%. Given that Geron Corp. has higher upside potential than Corvus Pharmaceuticals, Inc., analysts believe Geron Corp. is more attractive than Corvus Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRVSCorvus Pharmaceuticals, Inc.6 0 0 GERNGeron Corp.3 1 1 -
Is CRVS or GERN More Risky?
Corvus Pharmaceuticals, Inc. has a beta of 0.703, which suggesting that the stock is 29.727% less volatile than S&P 500. In comparison Geron Corp. has a beta of 0.594, suggesting its less volatile than the S&P 500 by 40.567%.
-
Which is a Better Dividend Stock CRVS or GERN?
Corvus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corvus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Geron Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRVS or GERN?
Corvus Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Geron Corp. quarterly revenues of $47.2M. Corvus Pharmaceuticals, Inc.'s net income of -$10.2M is higher than Geron Corp.'s net income of -$18.4M. Notably, Corvus Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Geron Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corvus Pharmaceuticals, Inc. is -- versus 4.97x for Geron Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRVSCorvus Pharmaceuticals, Inc.-- -- -- -$10.2M GERNGeron Corp.4.97x -- $47.2M -$18.4M
-
Which has Higher Returns CRVS or JAGX?
Jaguar Health, Inc. has a net margin of -- compared to Corvus Pharmaceuticals, Inc.'s net margin of -312.94%. Corvus Pharmaceuticals, Inc.'s return on equity of -30.6% beat Jaguar Health, Inc.'s return on equity of -524.57%.
Company Gross Margin Earnings Per Share Invested Capital CRVSCorvus Pharmaceuticals, Inc.-- -$0.12 $72.8M JAGXJaguar Health, Inc.64.58% -$6.28 $36.3M -
What do Analysts Say About CRVS or JAGX?
Corvus Pharmaceuticals, Inc. has a consensus price target of $33.33, signalling upside risk potential of 61.03%. On the other hand Jaguar Health, Inc. has an analysts' consensus of $25.50 which suggests that it could grow by 3680.02%. Given that Jaguar Health, Inc. has higher upside potential than Corvus Pharmaceuticals, Inc., analysts believe Jaguar Health, Inc. is more attractive than Corvus Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRVSCorvus Pharmaceuticals, Inc.6 0 0 JAGXJaguar Health, Inc.1 0 0 -
Is CRVS or JAGX More Risky?
Corvus Pharmaceuticals, Inc. has a beta of 0.703, which suggesting that the stock is 29.727% less volatile than S&P 500. In comparison Jaguar Health, Inc. has a beta of -0.422, suggesting its less volatile than the S&P 500 by 142.19%.
-
Which is a Better Dividend Stock CRVS or JAGX?
Corvus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jaguar Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corvus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Jaguar Health, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRVS or JAGX?
Corvus Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Jaguar Health, Inc. quarterly revenues of $3.1M. Corvus Pharmaceuticals, Inc.'s net income of -$10.2M is lower than Jaguar Health, Inc.'s net income of -$9.6M. Notably, Corvus Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Jaguar Health, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corvus Pharmaceuticals, Inc. is -- versus 0.23x for Jaguar Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRVSCorvus Pharmaceuticals, Inc.-- -- -- -$10.2M JAGXJaguar Health, Inc.0.23x -- $3.1M -$9.6M
-
Which has Higher Returns CRVS or KRYS?
Krystal Biotech, Inc. has a net margin of -- compared to Corvus Pharmaceuticals, Inc.'s net margin of 81.15%. Corvus Pharmaceuticals, Inc.'s return on equity of -30.6% beat Krystal Biotech, Inc.'s return on equity of 19.91%.
Company Gross Margin Earnings Per Share Invested Capital CRVSCorvus Pharmaceuticals, Inc.-- -$0.12 $72.8M KRYSKrystal Biotech, Inc.94.21% $2.66 $1.1B -
What do Analysts Say About CRVS or KRYS?
Corvus Pharmaceuticals, Inc. has a consensus price target of $33.33, signalling upside risk potential of 61.03%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $288.70 which suggests that it could grow by 3.39%. Given that Corvus Pharmaceuticals, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Corvus Pharmaceuticals, Inc. is more attractive than Krystal Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRVSCorvus Pharmaceuticals, Inc.6 0 0 KRYSKrystal Biotech, Inc.11 0 0 -
Is CRVS or KRYS More Risky?
Corvus Pharmaceuticals, Inc. has a beta of 0.703, which suggesting that the stock is 29.727% less volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.705%.
-
Which is a Better Dividend Stock CRVS or KRYS?
Corvus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corvus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRVS or KRYS?
Corvus Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Krystal Biotech, Inc. quarterly revenues of $97.8M. Corvus Pharmaceuticals, Inc.'s net income of -$10.2M is lower than Krystal Biotech, Inc.'s net income of $79.4M. Notably, Corvus Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Krystal Biotech, Inc.'s PE ratio is 41.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corvus Pharmaceuticals, Inc. is -- versus 22.32x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRVSCorvus Pharmaceuticals, Inc.-- -- -- -$10.2M KRYSKrystal Biotech, Inc.22.32x 41.88x $97.8M $79.4M
-
Which has Higher Returns CRVS or PSTV?
Plus Therapeutics, Inc. has a net margin of -- compared to Corvus Pharmaceuticals, Inc.'s net margin of -316.61%. Corvus Pharmaceuticals, Inc.'s return on equity of -30.6% beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CRVSCorvus Pharmaceuticals, Inc.-- -$0.12 $72.8M PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About CRVS or PSTV?
Corvus Pharmaceuticals, Inc. has a consensus price target of $33.33, signalling upside risk potential of 61.03%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $6.38 which suggests that it could grow by 2694.83%. Given that Plus Therapeutics, Inc. has higher upside potential than Corvus Pharmaceuticals, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Corvus Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRVSCorvus Pharmaceuticals, Inc.6 0 0 PSTVPlus Therapeutics, Inc.3 0 0 -
Is CRVS or PSTV More Risky?
Corvus Pharmaceuticals, Inc. has a beta of 0.703, which suggesting that the stock is 29.727% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.845, suggesting its less volatile than the S&P 500 by 15.456%.
-
Which is a Better Dividend Stock CRVS or PSTV?
Corvus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corvus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRVS or PSTV?
Corvus Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Corvus Pharmaceuticals, Inc.'s net income of -$10.2M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Corvus Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corvus Pharmaceuticals, Inc. is -- versus 3.66x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRVSCorvus Pharmaceuticals, Inc.-- -- -- -$10.2M PSTVPlus Therapeutics, Inc.3.66x -- $1.4M -$4.4M
-
Which has Higher Returns CRVS or REGN?
Regeneron Pharmaceuticals, Inc. has a net margin of -- compared to Corvus Pharmaceuticals, Inc.'s net margin of 21.74%. Corvus Pharmaceuticals, Inc.'s return on equity of -30.6% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.
Company Gross Margin Earnings Per Share Invested Capital CRVSCorvus Pharmaceuticals, Inc.-- -$0.12 $72.8M REGNRegeneron Pharmaceuticals, Inc.85.9% $7.86 $34B -
What do Analysts Say About CRVS or REGN?
Corvus Pharmaceuticals, Inc. has a consensus price target of $33.33, signalling upside risk potential of 61.03%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $842.42 which suggests that it could grow by 12.75%. Given that Corvus Pharmaceuticals, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Corvus Pharmaceuticals, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRVSCorvus Pharmaceuticals, Inc.6 0 0 REGNRegeneron Pharmaceuticals, Inc.17 8 0 -
Is CRVS or REGN More Risky?
Corvus Pharmaceuticals, Inc. has a beta of 0.703, which suggesting that the stock is 29.727% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.965%.
-
Which is a Better Dividend Stock CRVS or REGN?
Corvus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.48% to investors and pays a quarterly dividend of $0.88 per share. Corvus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CRVS or REGN?
Corvus Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Corvus Pharmaceuticals, Inc.'s net income of -$10.2M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Corvus Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corvus Pharmaceuticals, Inc. is -- versus 5.62x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRVSCorvus Pharmaceuticals, Inc.-- -- -- -$10.2M REGNRegeneron Pharmaceuticals, Inc.5.62x 17.84x $3.9B $844.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
40
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Sell
34
PFSI alert for Jan 31
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Buy
60
JNUG alert for Jan 31
Direxion Daily Junior Gold Miners Idx Bull 2X Shs [JNUG] is down 26.98% over the past day.
